Optimal Treatments for NSCLC Patients Harboring Primary or Acquired Amplification

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired Amplification

Background : In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However, the relative efficacy of different therapeutics in primary NSCLC patients with MET amplification and the treatment options...

Full description

Bibliographic Details
Main Authors:	Dantong Sun MD, Junyan Tao MD, Weihua Yan MD, Jingjuan Zhu MD, Hai Zhou MD, Yingying Sheng MD, Chaofan Xue MD, Hong Li PhD, Helei Hou MD, PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-09-01
Series:	Technology in Cancer Research & Treatment
Online Access:	https://doi.org/10.1177/15330338221128414

Similar Items

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021-11-01)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
by: Kathryn C. Arbour, MD, et al.
Published: (2022-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
by: Liesbeth M. Hondelink, MD, et al.
Published: (2021-12-01)

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
by: Hirotsugu Kenmotsu, MD, PhD, et al.
Published: (2024-11-01)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
by: Zichen Zhao, MD, et al.
Published: (2022-06-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
by: Catherine Daniel, MD, PhD, et al.
Published: (2020-11-01)

Long-Term Recurrence of Completely Resected NSCLC
by: Katsuhiro Masago, MD, PhD, et al.
Published: (2020-09-01)

RET Fusion Testing in Patients With NSCLC: The RETING Study
by: Esther Conde, MD, PhD, et al.
Published: (2024-04-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-06-01)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
by: Daiki Ikarashi, MD, PhD, et al.
Published: (2021-10-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
by: Shannon S. Zhang, MD, et al.
Published: (2022-09-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
by: Taichi Miyawaki, MD, et al.
Published: (2020-06-01)

Targeting MET in NSCLC: An Ever-Expanding Territory
by: Ying Han, MD, et al.
Published: (2024-02-01)

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
by: Akira Hamada, MD, et al.
Published: (2022-05-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
by: Daichi Fujimoto, MD, et al.
Published: (2022-02-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report
by: Chetan V. Vakkalagadda, MD, et al.
Published: (2023-12-01)

Detection of Tumor DNA in Bronchoscopic Fluids in Peripheral NSCLC: A Proof-of-Concept Study
by: Gwenaëlle Arhant, MD, et al.
Published: (2024-02-01)

Prognostic Significance of the Proposed Residual Tumor Classification in Patients With NSCLC After Sleeve Lobectomy
by: Tao Chen, PhD, et al.
Published: (2023-10-01)

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
by: Yuki Katayama, MD, PhD, et al.
Published: (2024-03-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL
by: Shigehiro Yagishita, MD, PhD, et al.
Published: (2024-07-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study
by: Donglai Chen, MD, et al.
Published: (2020-09-01)

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
by: Marcin Nicoś, PhD, et al.
Published: (2022-12-01)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
by: Hitomi Jo, MD, PhD, et al.
Published: (2023-04-01)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
by: Pedro Rocha, MD, et al.
Published: (2021-01-01)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
by: Junyan Tao, et al.
Published: (2020-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
by: Shiting Xu, MD, et al.
Published: (2022-04-01)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
by: Alexander Drilon, MD, et al.
Published: (2022-06-01)